Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts.
Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts.
复制标题
DOI：
10.1128/msphere.00224-21
复制
发表时间：
2021-04-21
期刊：
影响因子：
4.8
通讯作者：
Chandran K
中科院分区：
文献类型：
--
作者：
Bortz RH 3rd;Florez C;Laudermilch E;Wirchnianski AS;Lasso G;Malonis RJ;Georgiev GI;Vergnolle O;Herrera NG;Morano NC;Campbell ST;Orner EP;Mengotto A;Dieterle ME;Fels JM;Haslwanter D;Jangra RK;Celikgil A;Kimmel D;Lee JH;Mariano MC;Nakouzi A;Quiroz J;Rivera J;Szymczak WA;Tong K;Barnhill J;Forsell MNE;Ahlm C;Stein DT;Pirofski LA;Goldstein DY;Garforth SJ;Almo SC;Daily JP;Prystowsky MB;Faix JD;Fox AS;Weiss LM;Lai JR;Chandran K
由严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的 2019 年冠状病毒病 (COVID-19) 全球大流行继续给社会和医疗保健系统带来巨大负担。 COVID-19 控制工作的一个关键组成部分是血清学检测，以确定 SARS-CoV-2 暴露的社区患病率，并量化个体对先前 SARS-CoV-2 感染或疫苗接种的免疫反应。在这里，我们描述了一种实验室开发的抗体测试，该测试使用现成的研究级试剂以高灵敏度和特异性检测患者血液样本中的 SARS-CoV-2 暴露情况。我们进一步表明，这种灵敏的测试可以通过单个样本测量来估计病毒刺突特异性 IgG 滴度，从而提供一种简单且可扩展的方法来测量个体免疫反应的强度。该测试的准确性、适应性和成本效益使其成为当前 COVID-19 大流行中临床部署的绝佳选择。重要性 血清学监测已成为 COVID-19 大流行期间的重要公共卫生工具。 SARS-CoV-2 感染或疫苗接种后保护性抗体和血清转化的检测有助于指导患者护理计划和公共卫生政策。血清学测试可以检测针对过去感染的抗体；因此，它们可以帮助克服分子测试只能检测活动性感染的缺点。这很重要，特别是考虑到许多 COVID-19 患者没有症状。在本研究中，我们描述了一种基于酶联免疫吸附测定 (ELISA) 的定性和定量血清学测试，用于测量针对 SARS-CoV-2 刺突糖蛋白的 IgG 和 IgA 抗体。该测试可以使用常用的实验室试剂和设备进行部署，并显示出高特异性和灵敏度。此外，我们证明可以通过单次测量来估计患者样本中的 IgG 滴度，从而使该检测能够在高通量临床环境中使用。
The coronavirus disease 2019 (COVID-19) global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to place an immense burden on societies and health care systems. A key component of COVID-19 control efforts is serological testing to determine the community prevalence of SARS-CoV-2 exposure and quantify individual immune responses to prior SARS-CoV-2 infection or vaccination. Here, we describe a laboratory-developed antibody test that uses readily available research-grade reagents to detect SARS-CoV-2 exposure in patient blood samples with high sensitivity and specificity. We further show that this sensitive test affords the estimation of viral spike-specific IgG titers from a single sample measurement, thereby providing a simple and scalable method to measure the strength of an individual’s immune response. The accuracy, adaptability, and cost-effectiveness of this test make it an excellent option for clinical deployment in the ongoing COVID-19 pandemic. IMPORTANCE Serological surveillance has become an important public health tool during the COVID-19 pandemic. Detection of protective antibodies and seroconversion after SARS-CoV-2 infection or vaccination can help guide patient care plans and public health policies. Serology tests can detect antibodies against past infections; consequently, they can help overcome the shortcomings of molecular tests, which can detect only active infections. This is important, especially when considering that many COVID-19 patients are asymptomatic. In this study, we describe an enzyme-linked immunosorbent assay (ELISA)-based qualitative and quantitative serology test developed to measure IgG and IgA antibodies against the SARS-CoV-2 spike glycoprotein. The test can be deployed using commonly available laboratory reagents and equipment and displays high specificity and sensitivity. Furthermore, we demonstrate that IgG titers in patient samples can be estimated from a single measurement, enabling the assay’s use in high-throughput clinical environments.